Axelrod and colleagues published a letter in the journal Leukemia (advance online publication 8 October 2013; doi: 10.1038/leu.2013.249) describing in vitro evidence of a synergistic response when combining carfilzomib and ibrutinib in mantle cell lymphoma. They are planning a phase 1/2 trial in that indication.
Given how myeloma responds to proteasome inhibition, the addition of ibrutinib is an interesting proposition.
I entered the trial number at ClinicalTrials.gov and found that the trial was listed, but not yet recruiting. The active trial for ibrutinib in MM is NCT01478581, which is now recruiting. This trial is for relapsed/refractory MM patients and uses Ibrutinib with and without dexamethasone. Preliminary completion of this trial is expected in July of 2015.